ENTRY       D11083                      Drug
NAME        Brolucizumab (USAN/INN);
            Brolucizumab (genetical recombination) (JAN);
            Brolucizuab-dbll;
            Beovu (TN)
PRODUCT     BEOVU (Novartis Pharmaceuticals Corporation)
FORMULA     C1164H1768N310O372S8
EXACT_MASS  26296.6724
MOL_WEIGHT  26312.8665
SEQUENCE    MEIVMTQSPS TLSASVGDRV IITCQASEII HSWLAWYQQK PGKAPKLLIY LASTLASGVP
            SRFSGSGSGA EFTLTISSLQ PDDFATYYCQ NVYLASTNGA NFGQGTKLTV LGGGGGSGGG
            GSGGGGSGGG GSEVQLVESG GGLVQPGGSL RLSCTASGFS LTDYYYMTWV RQAPGKGLEW
            VGFIDPDDDP YYATWAKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAG GDHNSGWGLD
            IWGQGTLVTV SS
            (Disulfide bridge: 24-89, 154-228)
  TYPE      Peptide
REMARK      Therapeutic category: 1319
            ATC code: S01LA06
            Product: D11083<JP/US>
EFFICACY    Age-related macular degeneration therapeutic agent, Anti-VEGF antibody
  DISEASE   Age-related macular degeneration [DS:H00821]
  TYPE      Monoclonal antibody
COMMENT     Treatment of wet age-related macular degeneration
TARGET      VEGFA [HSA:7422] [KO:K05448]
  PATHWAY   hsa04370(7422)  VEGF signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             S SENSORY ORGANS
              S01 OPHTHALMOLOGICALS
               S01L OCULAR VASCULAR DISORDER AGENTS
                S01LA Antineovascularisation agents
                 S01LA06 Brolucizumab
                  D11083  Brolucizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Ophthalmic Agents
              Ophthalmic Agents, Other
               Vascular Endothelial Growth Factor (VEGF) Inhibitor
                Brolucizumab
                 D11083  Brolucizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              13  Agents affecting sensory organs
               131  Ophthalmic agents
                1319  Others
                 D11083  Brolucizumab (USAN/INN); Brolucizumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Growth factors (RTK-binding)
                VEGFA
                 D11083  Brolucizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11083
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11083
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11083
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11083
DBLINKS     CAS: 1531589-13-5
            PubChem: 375581030
///
